Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: From biology to the bedside

Girolamo Ranieri, Aldo Maria Roccaro, Angelo Vacca, Domenico Ribatti

Research output: Contribution to journalArticle

Abstract

Thymidine phosphorylase (TP), also known as platelet derived endothelial cell growth factor (PD-ECGF), is an enzyme involved in thymidine synthesis and degradation and exerts an angiogenic activity, whereas N4 pentyloxycarbonyl- 5'-deoxy-5-fluorocytidine, commonly called capecitabine (CAP), is a TP-activated oral fluorpyrimidine, which generates 5-fluorouracil (5-FU) within tumours. In addition to its classic antitumour activity, recent studies suggest that CAP may act as an antiangiogenetic molecule. Assessment of tumour microvessel density as expressed by endothelial cell TP positivity may identify the most vascularized and hence CAP-sensitive tumours. This review summarizes: (i) the biochemical and tissue expression of TP; (ii) the pharmacological profile of CAP as an anti-cancer compound and the central role of TP in its activation; (iii) the potential antiangiogenetic role of TP-activated CAP in tumours.

Original languageEnglish
Pages (from-to)171-183
Number of pages13
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume1
Issue number2
DOIs
Publication statusPublished - 2006

Keywords

  • Angiogenesis
  • Anti-angiogenesis
  • Thymidine phosphorylase
  • Tumour progression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)
  • Drug Discovery

Fingerprint Dive into the research topics of 'Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: From biology to the bedside'. Together they form a unique fingerprint.

  • Cite this